

Corrigendum

Corrigendum to “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial”

**K. Watanabe,¹ A. Shimada,² K. Miyaki,³ A. Hirakata,⁴ K. Matsuoka,²
K. Omae,⁵ and I. Takei⁶**

¹Center for Kampo Medicine, Faculty of Environment and Information Study, Keio University School of Medicine, 5322 Endo, Fujisawa, Kanagawa 252-0882, Japan

²Division of Internal Medicine, Saiseikai Central Hospital, 1-14-17 Mita, Minato-ku, Tokyo 108-0073, Japan

³Department of Clinical Research and Informatics, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

⁴Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan

⁵Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

⁶Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, Japan

Correspondence should be addressed to K. Watanabe; watanabekenji@keio.jp

Received 26 January 2016; Accepted 19 June 2016

Copyright © 2016 K. Watanabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial” [1], we have noticed inadvertent errors. We would like to correct the errors here. These errors do not change the scientific conclusions of the paper.

(1) The abbreviation “DN” in the third paragraph of Section 2.4 “Primary and Secondary Outcomes” did not mean “diabetic nephropathy” and should be corrected as “diabetic neuropathy.”

(2) Section 3.1 “Participants Registration, Allocation, Follow-Up, and Analysis” should be corrected as follows: A total of 332 patients were registered for this clinical trial (Figure 1), among which 183 patients were excluded because of being out of criteria. Main reason of the exclusion was the retinopathy. Even though, in the regular ophthalmological check, these patients matched the inclusion criteria, fundus photography revealed that these patients did not match the inclusion criteria. Another reason was out of goshajinkigan pattern. This was relatively difficult for the physician who contributed to this study. As a result, 149 patients were

allocated to goshajinkigan (GJG) group ($n = 100$) and to control group ($n = 49$).

(3) Section 3.4 “Secondary Outcomes” should be corrected as follows: The hazard ratio was calculated as 0.436 (95% CI: 0.198–0.962), and the P value was 0.030 determined by the log-rank test (Figure 5).

References

- [1] K. Watanabe, A. Shimada, K. Miyaki et al., “Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2014, Article ID 128726, 8 pages, 2014.